.jpg)
The CliniMACS Prodigy® NK Cell Transduction (NKCT) Process simplifies and standardizes the manufacture of CAR NK cells. Our automated, closed system addresses the key challenges of scalability, speed, and GMP compliance, enabling efficient and reproducible manufacturing from early development through to commercialization. Proven in numerous clinical programs, the platform reduces manual steps, minimizes variability, and shortens time-to-clinic. Partner with us and turn new frontiers into proven solutions.
*In experiments run across 3 donors and multiple constructs. Based on data collected through 2024.
Miltenyi Biotec does not guarantee any specific results, or that batches will fully conform with any particular specifications. Individual success rate may vary based on factors such as client specifications.
Our two-step clinical-grade NK cell separation process efficiently removes T cells via CD3+ cell depletion and purifies NK cells via CD56+ cell enrichment. The resulting cell product consists of highly pure and viable NK cells, with a minimal presence of other immune cell types.
Download the brochure on our NK cell manufacturing solutions.
Our automated CliniMACS Prodigy NK Cell Transduction Process has been validated in industry and numerous clinical studies. It is designed for standardized and reliable cell manufacturing, delivering excellent transduction efficiencies and target cell frequencies.
